# Psilocybin

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/psilocybin-technology
Canonical HTML page: https://getbiobrief.com/entity/psilocybin-technology

## Timeline

- **2024**: Phase 3 Trials — Large-scale multi-site trials aim to provide definitive data for regulatory approval.
- **2022**: SAP Expansion — Canada amends the Special Access Program to include restricted psychedelic substances.
- **2020**: Regulatory Shift — Health Canada begins granting Section 56 exemptions for terminally ill patients.
- **2016**: Foundational Research — Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.

## Recent coverage (4 stories)

### Psychedelics Outperform Nicotine Patches in Landmark Smoking Cessation Study
2026-03-17 16:00:29 · Sentiment: Positive · Impact: 7/10 · Sources: 2

A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
Full story: https://getbiobrief.com/story/psychedelics-vs-nicotine-patches-smoking-cessation

### Psilocybin Therapy Shows Unprecedented Efficacy in Smoking Cessation Trials
2026-03-10 16:53:46 · Sentiment: Positive · Impact: 7/10 · Sources: 3

A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Full story: https://getbiobrief.com/story/psilocybin-smoking-cessation-clinical-trial-results

### Psilocybin Shows Clinical Promise in Easing End-of-Life Existential Distress
2026-03-06 15:49:59 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Full story: https://getbiobrief.com/story/psilocybin-end-of-life-clinical-promise

### Psyence BioMed Secures Supply Chain via Strategic PsyLabs Equity Investment
2026-02-21 00:40:46 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.
Full story: https://getbiobrief.com/story/psyence-biomed-psylabs-equity-investment-put-option

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.